[1]张艳,李明浩.参松养心胶囊联合华法林抗凝治疗心房颤动患者的临床效果观察[J].内科,2019,14(06):679-682.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.15]
 ZHANG Yan,LI Minghao.Clinical effect observation on Shensong Yangxin capsule combined with warfarin anticoagulation in patients with atrial fibrillation[J].Internal Medicine of China,2019,14(06):679-682.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.15]
点击复制

参松养心胶囊联合华法林抗凝治疗心房颤动患者的临床效果观察()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
14卷
期数:
2019年06
页码:
679-682
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Clinical effect observation on Shensong Yangxin capsule combined with warfarin anticoagulation in patients with atrial fibrillation
文章编号:
1673-7768(2019)06-0679-04
作者:
张艳1李明浩2
1 南阳市第三人民医院内科,2 南阳市第二人民医院神经内科,河南省南阳市473000
Author(s):
ZHANG Yan1 LI Minghao2
1 Department of Internal Medicine, Nanyang Third People′s Hospital, 2 Department of Neurology, Nanyang Second People′s Hospital, Nanyang 473000, Henan Province, China
关键词:
心房颤动参松养心胶囊华法林心功能
Keywords:
Atrial fibrillation Shensong Yangxin capsule Warfarin Cardiac function
分类号:
R 541
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2019.06.15
文献标志码:
A
摘要:
目的探讨参松养心胶囊联合华法林抗凝治疗对心房颤动患者临床症状、心功能的影响。方法选取2016年3月至2018年2月本院收治的心房颤动患者98例为研究对象,随机分为对照组和观察组,每组49例。对照组患者口服华法林钠片治疗,观察组患者口服华法林钠片+参松养心胶囊治疗,两组患者均连续治疗3个月。比较两组患者的临床疗效、房颤发作频率、房颤发作持续时间、心功能、血清超敏C反应蛋白(hs-CRP)水平、基质金属蛋白酶-2(MMP-2)水平及治疗期间的不良反应发生情况。结果治疗3个月,观察组患者的治疗总有效率(89.80%)显著高于对照组(73.47%),临床疗效显著优于对照组,差异有统计学意义(P<0.05);观察组患者的房颤发作频率、发作持续时间、左心室舒张末期内径(LVEDd)均显著小(短)于对照组,左心室射血分数(LVEF)显著高于对照组,差异有统计学意义(P<0.05);观察组患者的血清hs-CRP、MMP-2水平均低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论参松养心胶囊联合华法林抗凝治疗心房颤动患者临床效果确切,可显著缓解临床症状、改善心功能、降低血清hs-CRP及MMP-2水平,治疗安全性高。
Abstract:
ObjectiveTo investigate the effects of Shensong Yangxin capsule combined with warfarin anticoagulation on clinical symptoms and cardiac function in patients with atrial fibrillation. MethodsA total of 98 patients with atrial fibrillation admitted to our hospital from March 2016 to February 2018 were selected as the research subjects, and were randomly divided into control group and observation group, with 49 cases in each group. Patients in the control group were administered orally warfarin sodium tablets, whereas patients in the observation group were administered orally warfarin sodium tablets + Shensong Yangxin capsules, for three-month continuous treatment in both groups. The clinical efficacy, frequency of atrial fibrillation, duration of atrial fibrillation, cardiac function, serum high-sensitivity C-reactive protein (hs-CRP) level, matrix metalloproteinase-2 (MMP-2) level, and the prevalence of adverse reactions during treatment period were compared between the two groups. ResultsAfter 3 months of treatment, the total effective rate (89.80%) in the observation group was significantly higher than that in the control group (73.47%), and the clinical efficacy was significantly superior to that in the control group, with the statistically significant differences (P<0.05). In comparison with the control group, patients in the observation group obtained a lower frequency of atrial fibrillation, a shorter outbreak duration, and a smaller left ventricular end-diastolic diameter (LVEDd), whereas a higher left ventricular ejection fraction (LVEF), with the statistically significant differences (P<0.05). The levels of serum hs-CRP and MMP-2 in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). ConclusionThe clinical effect of Shensong Yangxin capsule combined with warfarin anticoagulation on atrial fibrillation is precise, for it can prominently relieve clinical symptoms, improve cardiac function, decrease serum hs-CRP and MMP-2 levels, and thus the treatment is highly safe.

相似文献/References:

[1]李群 陆首玲 刘尚 刘斌.华法林和利伐沙班治疗心房颤动临床疗效对比分析[J].内科,2015,(04):463.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.04.10]
 [J].Internal Medicine of China,2015,(06):463.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.04.10]
[2]滕强丰 覃伟武 曾昭辉.稳心颗粒配合131I治疗Graves病合并心房颤动的疗效观察[J].内科,2013,(03):244.
 [J].Internal Medicine of China,2013,(06):244.
[3]廖波.房颤患者的心电图f波特点与左房内径分析[J].内科,2011,(05):425.
 LIAO Bo.Analysis of f wave and left atrial dimension in patients with atrial fibrillation[J].Internal Medicine of China,2011,(06):425.
[4]李法宁,匡平,陈原,等.参松养心胶囊联合胺碘酮治疗对阵发性房颤患者血清MMP-2、hs-CRP水平的影响[J].内科,2016,(05):694.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.05.07]
 LI Fa-ning,KUANG Ping,CHEN Yuan,et al.Effect of Shensongyangxin capsules combined with amiodarone on MMP-2 and hs-CRP of patients with paroxysmal atrial fibrillation[J].Internal Medicine of China,2016,(06):694.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.05.07]
[5]袁棋炎,谢金丹,石理*.华法林治疗80岁及以上老年心房颤动患者临床观察[J].内科,2016,(06):842.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.06.08]
 YUAN Qiyan,XIE Jindan,SSHI Li.Clinical observation of warfarin in the treatment of 80 years and older patients with atrial fibrillation[J].Internal Medicine of China,2016,(06):842.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.06.08]
[6]刘庆模.急性缺血性脑卒中患者早期神经功能恶化的影响因素研究[J].内科,2017,12(03):323.[doi:DOI:10.16121/j.cnki.cn45 1347/r.2017.03.08]
 LIU Qingmo.Risk factors of early neurological deterioration in patients with acute ischemic stroke[J].Internal Medicine of China,2017,12(06):323.[doi:DOI:10.16121/j.cnki.cn45 1347/r.2017.03.08]
[7]何显荣,余新东,瞿珍清.基于“互联网+”的华法林抗凝治疗管理心房颤动患者研究▲[J].内科,2018,13(03):389.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2018.03.35]
 [J].Internal Medicine of China,2018,13(06):389.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2018.03.35]
[8]吕祥威,徐彤彤*,赵位昆.心房颤动治疗方式的选择与哲学思考▲[J].内科,2018,13(04):610.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2018.04.21]

更新日期/Last Update: 2020-01-03